

Byoung Seok Ye

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7270530/publications.pdf>

Version: 2024-02-01

143
papers

2,751
citations

196777

29
h-index

299063

42
g-index

165
all docs

165
docs citations

165
times ranked

4799
citing authors

#	ARTICLE	IF	CITATIONS
1	The relationship between cognitive function and competence in inhaler technique in older adults with airway disease. <i>Geriatric Nursing</i> , 2022, 43, 15-20.	0.9	1
2	White matter connectivity networks predict levodopa-induced dyskinesia in Parkinson's disease. <i>Journal of Neurology</i> , 2022, 269, 2948-2960.	1.8	3
3	Association Between White Matter Connectivity and Early Dementia in Patients With Parkinson Disease. <i>Neurology</i> , 2022, 98, .	1.5	8
4	Interrelation of striatal dopamine, brain metabolism and cognition in dementia with Lewy bodies. <i>Brain</i> , 2022, 145, 4448-4458.	3.7	9
5	Protective Effect of Renin-Angiotensin System Inhibitors on Parkinson's Disease: A Nationwide Cohort Study. <i>Frontiers in Pharmacology</i> , 2022, 13, 837890.	1.6	29
6	Effects of Alzheimer and Lewy Body Disease Pathologies on Brain Metabolism. <i>Annals of Neurology</i> , 2022, 91, 853-863.	2.8	7
7	Association of β -Amyloid and Basal Forebrain With Cortical Thickness and Cognition in Alzheimer and Lewy Body Disease Spectra. <i>Neurology</i> , 2022, 98, .	1.5	10
8	Effects of Alzheimer's genetic risk scores and CSF biomarkers in de novo Parkinson's Disease. <i>Npj Parkinson's Disease</i> , 2022, 8, 57.	2.5	2
9	Association of nonalcoholic fatty liver disease with incident dementia later in life among elderly adults. <i>Clinical and Molecular Hepatology</i> , 2022, 28, 481-482.	4.5	2
10	Gut microbiota-derived metabolite trimethylamine N-oxide as a biomarker in early Parkinson's disease. <i>Nutrition</i> , 2021, 83, 111090.	1.1	36
11	The pattern of FP-CIT PET in pure white matter hyperintensities-related vascular parkinsonism. <i>Parkinsonism and Related Disorders</i> , 2021, 82, 1-6.	1.1	2
12	Relationship between Hearing Loss and Dementia Differs According to the Underlying Mechanism.		

#	ARTICLE	IF	CITATIONS
19	Different patterns of β^2 -amyloid deposition in patients with Alzheimer's disease according to the presence of mild parkinsonism. <i>Neurobiology of Aging</i> , 2021, 101, 199-206.	1.5	2
20	Baseline cognitive profile is closely associated with long-term motor prognosis in newly diagnosed Parkinson's disease. <i>Journal of Neurology</i> , 2021, 268, 4203-4212.	1.8	8
21	Deep learning-based amyloid PET positivity classification model in the Alzheimer's disease continuum by using 2-[18 F]FDG PET. <i>EJNMMI Research</i> , 2021, 11, 56.	1.1	20
22	Thematic and Frequency Analyses of Caregivers' Report on Communication-related Chief Complaints in Progressive Aphasia. <i>Communication Sciences and Disorders</i> , 2021, 26, 413-427.	0.1	0
23	Clinical and Dopamine Depletion Patterns in Hyposmia- and Dysautonomia-Dominant Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2021, 11, 1-11.	1.5	1
24	Implication of metabolic and dopamine transporter PET in dementia with Lewy bodies. <i>Scientific Reports</i> , 2021, 11, 14394.	1.6	7
25	Association of Dipeptidyl Peptidase-4 Inhibitor Use and Amyloid Burden in Patients With Diabetes and AD-Related Cognitive Impairment. <i>Neurology</i> , 2021, 97, e1110-e1122.	1.5	18
26	Diffusion tensor imaging-based pontine damage as a degeneration marker in synucleinopathy. <i>Journal of Neuroscience Research</i> , 2021, 99, 2922-2931.	1.3	1
27	Implication of Small Vessel Disease MRI Markers in Alzheimer's Disease and Lewy Body Disease. <i>Journal of Alzheimer's Disease</i> , 2021, 83, 545-556.	1.2	3
28	Effects of baseline serum uric acid and apolipoprotein E4 on longitudinal cognition and cerebral metabolism. <i>Neurobiology of Aging</i> , 2021, 106, 223-231.	1.5	8
29	Apolipoprotein E4, amyloid, and cognition in Alzheimer's and Lewy body disease. <i>Neurobiology of Aging</i> , 2021, 106, 45-54.	1.5	9
30	PET/CT for Brain Amyloid. <i>Clinical Nuclear Medicine</i> , 2021, 46, e133-e140.	0.7	3
31	Factors Associated With Behavioral and Psychological Symptoms of Dementia: Prospective Observational Study Using Actigraphy. <i>Journal of Medical Internet Research</i> , 2021, 23, e29001.	2.1	12
32	Extensive frontal focused ultrasound mediated blood-brain barrier opening for the treatment of Alzheimer's disease: a proof-of-concept study. <i>Translational Neurodegeneration</i> , 2021, 10, 44.	3.6	46
33	Effects of Alzheimer's disease and Lewy body disease on subcortical atrophy. <i>European Journal of Neurology</i> , 2020, 27, 318-326.	1.7	9
34	Distinguishing between dementia with Lewy bodies and Alzheimer's disease using metabolic patterns. <i>Neurobiology of Aging</i> , 2020, 87, 11-17.	1.5	15
35	Neural Correlates of Cognitive Performance in Alzheimer's Disease- and Lewy Bodies-Related Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2020, 73, 873-885.	1.2	4
36	Clinical and Striatal Dopamine Transporter Predictors of Mild Behavioral Impairment in Drug-Naive Parkinson Disease. <i>Clinical Nuclear Medicine</i> , 2020, 45, e463-e468.	0.7	9

#	ARTICLE	IF	CITATIONS
37	Factor analysisâ€‘derived cognitive profile predicting early dementia conversion in PD. <i>Neurology</i> , 2020, 95, e1650-e1659.	1.5	21
38	Minimal parkinsonism in the elderly is associated with striatal dopamine loss and pontine structural damage. <i>Parkinsonism and Related Disorders</i> , 2020, 81, 140-143.	1.1	6
39	Motor Cerebellar Connectivity and Future Development of Freezing of Gait in De Novo Parkinson's Disease. <i>Movement Disorders</i> , 2020, 35, 2240-2249.	2.2	17
40	Effects of APOE4 on Alzheimerâ€™s disease, Lewy body disease, cerebral amyloid deposition and cognitive dysfunction. <i>Alzheimer's and Dementia</i> , 2020, 16, e037300.	0.4	0
41	Alterations of cortical thickness and grayâ€‘white matter contrast in Alzheimerâ€™s disease and Lewy bodyâ€‘related cognitive impairment. <i>Alzheimer's and Dementia</i> , 2020, 16, e041245.	0.4	1
42	Clinical and striatal dopamine transporter predictors of Î²-amyloid in dementia with Lewy bodies. <i>Neurology</i> , 2020, 94, e1344-e1352.	1.5	17
43	Urate is closely linked to white matter integrity in multiple system atrophy. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 1029-1039.	1.7	4
44	White matter hyperintensities and risk of levodopaâ€‘induced dyskinesia in Parkinsonâ€™s disease. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 229-238.	1.7	16
45	Cognitive anosognosia is associated with frontal dysfunction and lower depression in Parkinsonâ€™s disease. <i>European Journal of Neurology</i> , 2020, 27, 951-958.	1.7	10
46	Dopaminergic Depletion, Î²â€‘Amyloid Burden, and Cognition in Lewy Body Disease. <i>Annals of Neurology</i> , 2020, 87, 739-750.	2.8	27
47	Impaired functional connectivity of sensorimotor network predicts recovery in drug-induced parkinsonism. <i>Parkinsonism and Related Disorders</i> , 2020, 74, 16-21.	1.1	5
48	Changes in plasma arylsulfatase A level as a compensatory biomarker of early Parkinsonâ€™s disease. <i>Scientific Reports</i> , 2020, 10, 5567.	1.6	7
49	Association between Olfactory Deficit and Motor and Cognitive Function in Parkinsonâ€™s Disease. <i>Journal of Movement Disorders</i> , 2020, 13, 133-141.	0.7	22
50	Cohort Profile: Firefighter Research on the Enhancement of Safety and Health (FRESH), a Prospective Cohort Study on Korean Firefighters. <i>Yonsei Medical Journal</i> , 2020, 61, 103.	0.9	17
51	Sexâ€‘specific association of urate and levodopaâ€‘induced dyskinesia in Parkinsonâ€™s disease. <i>European Journal of Neurology</i> , 2020, 27, 1948-1956.	1.7	5
52	White matter hyperintensities as a predictor of freezing of gait in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2019, 66, 105-109.	1.1	27
53	Beneficial effect of estrogen on nigrostriatal dopaminergic neurons in drug-naïve postmenopausal Parkinsonâ€™s disease. <i>Scientific Reports</i> , 2019, 9, 10531.	1.6	35
54	Cerebellar connectivity in Parkinson's disease with levodopaâ€‘induced dyskinesia. <i>Annals of Clinical and Translational Neurology</i> , 2019, 6, 2251-2260.	1.7	15

#	ARTICLE	IF	CITATIONS
55	Frontal atrophy as a marker for dementia conversion in Parkinson's disease with mild cognitive impairment. <i>Human Brain Mapping</i> , 2019, 40, 3784-3794.	1.9	41
56	Olfactory anosognosia is a predictor of cognitive decline and dementia conversion in Parkinson's disease. <i>Journal of Neurology</i> , 2019, 266, 1601-1610.	1.8	17
57	Distinct FP-CIT PET patterns of Alzheimer's disease with parkinsonism and dementia with Lewy bodies. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1652-1660.	3.3	11
58	Mild cognitive impairment reverts have a favorable cognitive prognosis and cortical integrity in Parkinson's disease. <i>Neurobiology of Aging</i> , 2019, 78, 168-177.	1.5	16
59	Effects of Lewy body disease and Alzheimer disease on brain atrophy and cognitive dysfunction. <i>Neurology</i> , 2019, 92, e2015-e2026.	1.5	28
60	Levodopa-induced dyskinesia is closely linked to progression of frontal dysfunction in PD. <i>Neurology</i> , 2019, 92, e1468-e1478.	1.5	16
61	P4572: NEURAL CORRELATES OF COGNITIVE PERFORMANCE IN ALZHEIMER'S DISEASE AND LEWY BODY DISEASE SPECTRA. <i>Alzheimer's and Dementia</i> , 2019, 15, P1538.	0.4	0
62	P4571: DISTINCT FP-CIT PET PATTERNS OF ALZHEIMER'S DISEASE WITH PARKINSONISM AND DEMENTIA WITH LEWY BODIES. <i>Alzheimer's and Dementia</i> , 2019, 15, P1538.	0.4	0
63	Gastrectomy and nigrostriatal dopaminergic depletion in de novo Parkinson's disease. <i>Movement Disorders</i> , 2019, 34, 299-301.	2.2	1
64	Longitudinal outcomes of amyloid positive versus negative amnesic mild cognitive impairments: a three-year longitudinal study. <i>Scientific Reports</i> , 2018, 8, 5557.	1.6	26
65	Effect of striatal dopamine depletion on cognition in de novo Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2018, 51, 43-48.	1.1	79
66	The moderating effect of religiosity on caregiving burden and depressive symptoms in caregivers of patients with dementia. <i>Aging and Mental Health</i> , 2018, 22, 141-147.	1.5	13
67	Presynaptic dopamine depletion determines the timing of levodopa-induced dyskinesia onset in Parkinson's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 423-431.	3.3	24
68	Effects of dopaminergic depletion and brain atrophy on neuropsychiatric symptoms in de novo Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 197-204.	0.9	19
69	Early-onset drug-induced parkinsonism after exposure to offenders implies nigrostriatal dopaminergic dysfunction. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 169-174.	0.9	14
70	P393: A NOMOGRAM FOR PREDICTING AMYLOID PET POSITIVITY IN AMNESTIC MILD COGNITIVE IMPAIRMENT. <i>Alzheimer's and Dementia</i> , 2018, 14, P1248.	0.4	0
71	O1305: DISTINCT PATTERN OF CORTICAL ATROPHY IN ALZHEIMER'S DISEASE AND LEWY BODY-RELATED COGNITIVE IMPAIRMENT ACROSS THE DISEASE SPAN. <i>Alzheimer's and Dementia</i> , 2018, 14, P254.	0.4	0
72	A Nomogram for Predicting Amyloid PET Positivity in Amnesic Mild Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2018, 66, 681-691.	1.2	38

#	ARTICLE	IF	CITATIONS
73	Amyloid- β -related and unrelated cortical thinning in dementia with Lewy bodies. <i>Neurobiology of Aging</i> , 2018, 72, 32-39.	1.5	25
74	Olfactory dysfunction in Alzheimer's disease and Lewy body-related cognitive impairment. <i>Alzheimer's and Dementia</i> , 2018, 14, 1243-1252.	0.4	42
75	The role of 18F-FP-CIT PET in differentiation of progressive supranuclear palsy and frontotemporal dementia in the early stage. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1585-1595.	3.3	20
76	Cerebrospinal Fluid Biomarkers for the Diagnosis of Alzheimer Disease in South Korea. <i>Alzheimer Disease and Associated Disorders</i> , 2017, 31, 13-18.	0.6	21
77	Influence of personality on depression, burden, and health-related quality of life in family caregivers of persons with dementia. <i>International Psychogeriatrics</i> , 2017, 29, 227-237.	0.6	32
78	Dementia-Predicting Cognitive Risk Score and Its Correlation with Cortical Thickness in Parkinson Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2017, 44, 203-212.	0.7	16
79	Prediction Model of Conversion to Dementia Risk in Subjects with Amnesic Mild Cognitive Impairment: A Longitudinal, Multi-Center Clinic-Based Study. <i>Journal of Alzheimer's Disease</i> , 2017, 60, 1579-1587.	1.2	30
80	Sleep Disturbance May Alter White Matter and Resting State Functional Connectivities in Parkinson's Disease. <i>Sleep</i> , 2017, 40, .	0.6	15
81	[P4]: EFFECT OF LEWY BODY DISEASE AND ALZHEIMER'S DISEASE ON COGNITION AND BRAIN ATROPHY. <i>Alzheimer's and Dementia</i> , 2017, 13, P1526.	0.4	0
82	[P2]: RISK SCORE FOR THE PREDICTION OF DEMENTIA RISK IN SUBJECTS WITH AMNESTIC MILD COGNITIVE IMPAIRMENT: A LONGITUDINAL, MULTI-CENTER CLINIC-BASED STUDY. <i>Alzheimer's and Dementia</i> , 2017, 13, P739.	0.4	0
83	[P4]: OLFATORY DYSFUNCTION IN ALZHEIMER AND LEWY BODY-RELATED COGNITIVE IMPAIRMENT: DIAGNOSTIC IMPLICATION AND ASSOCIATION WITH COGNITION AND BRAIN ATROPHY. <i>Alzheimer's and Dementia</i> , 2017, 13, P1524.	0.4	1
84	[P4]: CLINICAL FEATURES AND CORTICAL ATROPHY PATTERNS OF DEMENTIA WITH LEWY BODIES WITH AND WITHOUT AMYLOID β DEPOSITION. <i>Alzheimer's and Dementia</i> , 2017, 13, P1527.	0.4	0
85	Mesenchymal Stem Cells Stabilize Axonal Transports for Autophagic Clearance of β -Synuclein in Parkinsonian Models. <i>Stem Cells</i> , 2017, 35, 1934-1947.	1.4	30
86	Higher Physical Activity Is Associated with Increased Attentional Network Connectivity in the Healthy Elderly. <i>Frontiers in Aging Neuroscience</i> , 2016, 8, 198.	1.7	13
87	Striatal Dopamine Depletion Patterns and Early Non-Motor Burden in Parkinsons Disease. <i>PLoS ONE</i> , 2016, 11, e0161316.	1.1	11
88	Does serum uric acid act as a modulator of cerebrospinal fluid Alzheimer's disease biomarker related cognitive decline?. <i>European Journal of Neurology</i> , 2016, 23, 948-957.	1.7	37
89	The Role of Cerebrovascular Disease in Amyloid Deposition. <i>Journal of Alzheimer's Disease</i> , 2016, 54, 1015-1026.	1.2	12
90	Cognitive and Neuroanatomical Correlates in Early Versus Late Onset Parkinson's Disease Dementia. <i>Journal of Alzheimer's Disease</i> , 2016, 55, 485-495.	1.2	6

#	ARTICLE	IF	CITATIONS
91	P2-225: Dopaminergic Depletion in Anterior Caudate and Putamen Causes Cognitive Impairment in Parkinson's Disease. , 2016, 12, P708-P708.		0
92	P3-180: Effect of Vitamin B12 on Cognition. Alzheimer's and Dementia, 2016, 12, P889.	0.4	0
93	Decreased hemoglobin levels, cerebral small-vessel disease, and cortical atrophy: among cognitively normal elderly women and men. International Psychogeriatrics, 2016, 28, 147-156.	0.6	16
94	Impact of smoking on neurodegeneration and cerebrovascular disease markers in cognitively normal men. European Journal of Neurology, 2016, 23, 110-119.	1.7	18
95	P4-121: Neuroprotective Effect of Serum Uric Acid on Alzheimer's Disease is Mediated by Brain Metabolism Change. , 2016, 12, P1059-P1059.		0
96	Posterior Ventricular Enlargement to Differentiate Dementia with Lewy Bodies from Alzheimer's Disease. Journal of Alzheimer's Disease, 2016, 52, 1237-1243.	1.2	6
97	The Computerized Table Setting Test for Detecting Unilateral Neglect. PLoS ONE, 2016, 11, e0147030.	1.1	5
98	P2-147: The effect of education on cognition and cortical thickness in pure vascular mild cognitive impairment and dementia of the subcortical type. , 2015, 11, P542-P542.		0
99	Elevation of the Plasma A β 40/A β 42 Ratio as a Diagnostic Marker of Sporadic Early-Onset Alzheimer's Disease. Journal of Alzheimer's Disease, 2015, 48, 1043-1050.	1.2	33
100	Clinical and Neuropsychological Comparisons of Early-Onset Versus Late-Onset Frontotemporal Dementia: A CREDOS-FTD Study. Journal of Alzheimer's Disease, 2015, 45, 599-608.	1.2	19
101	Effects of Amyloid and Small Vessel Disease on White Matter Network Disruption. Journal of Alzheimer's Disease, 2015, 44, 963-975.	1.2	29
102	P3-098: Serum uric acid, cerebrospinal fluid marker of Alzheimer's disease and cognition. , 2015, 11, P657-P658.		0
103	Association of Body Fat Percentage and Waist-hip Ratio With Brain Cortical Thickness. Alzheimer Disease and Associated Disorders, 2015, 29, 279-286.	0.6	13
104	Apolipoprotein E4 Affects Topographical Changes in Hippocampal and Cortical Atrophy in Alzheimer's Disease Dementia: A Five-Year Longitudinal Study. Journal of Alzheimer's Disease, 2015, 44, 1075-1085.	1.2	11
105	Structural Brain Changes after Traditional and Robot-Assisted Multi-Domain Cognitive Training in Community-Dwelling Healthy Elderly. PLoS ONE, 2015, 10, e0123251.	1.1	83
106	Unstable Body Mass Index and Progression to Probable Alzheimer's Disease Dementia in Patients with Amnesic Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2015, 49, 483-491.	1.2	31
107	Higher education affects accelerated cortical thinning in Alzheimer's disease: a 5-year preliminary longitudinal study. International Psychogeriatrics, 2015, 27, 111-120.	0.6	16
108	Clinical effect of white matter network disruption related to amyloid and small vessel disease. Neurology, 2015, 85, 63-70.	1.5	79

#	ARTICLE	IF	CITATIONS
109	Effects of education on aging-related cortical thinning among cognitively normal individuals. <i>Neurology</i> , 2015, 85, 806-812.	1.5	54
110	Amyloid burden, cerebrovascular disease, brain atrophy, and cognition in cognitively impaired patients. <i>Alzheimer's and Dementia</i> , 2015, 11, 494.	0.4	61
111	Postmorbidity learning of saxophone playing in a patient with frontotemporal dementia. <i>Neurocase</i> , 2015, 21, 767-772.	0.2	15
112	Association between body mass index and cortical thickness: among elderly cognitively normal men and women. <i>International Psychogeriatrics</i> , 2015, 27, 121-130.	0.6	19
113	Contraversive Ocular Tilt Reaction After the Lateral Medullary Infarction. <i>Neurologist</i> , 2015, 19, 79-81.	0.4	9
114	Effects of amyloid and vascular markers on cognitive decline in subcortical vascular dementia. <i>Neurology</i> , 2015, 85, 1687-1693.	1.5	44
115	Hippocampal volume and shape in pure subcortical vascular dementia. <i>Neurobiology of Aging</i> , 2015, 36, 485-491.	1.5	37
116	Comparison of cortical thickness in patients with early-stage versus late-stage amnesic mild cognitive impairment. <i>European Journal of Neurology</i> , 2014, 21, 86-92.	1.7	34
117	Anatomical heterogeneity of Alzheimer disease. <i>Neurology</i> , 2014, 83, 1936-1944.	1.5	161
118	Synergistic Effects of Ischemia and β -Amyloid Burden on Cognitive Decline in Patients With Subcortical Vascular Mild Cognitive Impairment. <i>JAMA Psychiatry</i> , 2014, 71, 412.	6.0	90
119	Cortical thickness and hippocampal shape in pure vascular mild cognitive impairment and dementia of subcortical type. <i>European Journal of Neurology</i> , 2014, 21, 744-751.	1.7	56
120	Higher C-peptide levels are associated with regional cortical thinning in 1093 cognitively normal subjects. <i>European Journal of Neurology</i> , 2014, 21, 1318.	1.7	4
121	Effects of cerebrovascular disease and amyloid beta burden on cognition in subjects with subcortical vascular cognitive impairment. <i>Neurobiology of Aging</i> , 2014, 35, 254-260.	1.5	70
122	Hippocampal and cortical atrophy in amyloid-negative mild cognitive impairments: comparison with amyloid-positive mild cognitive impairment. <i>Neurobiology of Aging</i> , 2014, 35, 291-300.	1.5	30
123	Shape Changes of the Basal Ganglia and Thalamus in Alzheimer's Disease: A Three-Year Longitudinal Study. <i>Journal of Alzheimer's Disease</i> , 2014, 40, 285-295.	1.2	69
124	White Matter Hyperintensities are associated with Amyloid Burden in APOE4 Non-Carriers. <i>Journal of Alzheimer's Disease</i> , 2014, 40, 877-886.	1.2	34
125	The Heterogeneity and Natural History of Mild Cognitive Impairment of Visual Memory Predominant Type. <i>Journal of Alzheimer's Disease</i> , 2014, 43, 143-152.	1.2	12
126	P3-231: ASSOCIATION OF BODY FAT PERCENTAGE AND WAIST-HIP RATIO WITH BRAIN CORTICAL THICKNESS IN 1,777 COGNITIVELY NORMAL SUBJECTS. , 2014, 10, P715-P716.		0

#	ARTICLE	IF	CITATIONS
127	P4-145: BRAINSTEM MICROBLEEDS AFFECT MOTOR DEFICITS IN SUBCORTICAL VASCULAR COGNITIVE IMPAIRMENT. , 2014, 10, P842-P842.		0
128	P2-200: MICROSTRUCTURAL CHANGES OF WHITE MATTER IN PURE ALZHEIMER'S DISEASE AND PURE SUBCORTICAL VASCULAR DISEASE. , 2014, 10, P545-P545.		0
129	O5-01-01: EFFECTS OF AMYLOID AND CEREBROVASCULAR DISEASE ON ALTERED WHITE MATTER NETWORK IN COGNITIVELY IMPAIRED PATIENTS. , 2014, 10, P286-P287.		0
130	IC-P-186: EFFECTS OF AMYLOID AND CEREBROVASCULAR DISEASE ON ALTERED WHITE MATTER NETWORK IN COGNITIVELY IMPAIRED PATIENTS. , 2014, 10, P103-P104.		0
131	P4-334: DIFFERENTIAL ASSOCIATION BETWEEN CANCER INCIDENCE RISK AND ALZHEIMER'S DISEASE ACCORDING TO DEMENTIA MEDICATION. , 2014, 10, P910-P910.		0
132	Changes in subcortical structures in early- versus late-onset Alzheimer's disease. <i>Neurobiology of Aging</i> , 2013, 34, 1740-1747.	1.5	74
133	Effects of APOE ϵ 4 on brain amyloid, lacunar infarcts, and white matter lesions: a study among patients with subcortical vascular cognitive impairment. <i>Neurobiology of Aging</i> , 2013, 34, 2482-2487.	1.5	20
134	Amyloid Deposition in Early Onset versus Late Onset Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2013, 35, 813-821.	1.2	57
135	Effects of education on the progression of early- versus late-stage mild cognitive impairment. <i>International Psychogeriatrics</i> , 2013, 25, 597-606.	0.6	46
136	Individual Subject Classification of Mixed Dementia from Pure Subcortical Vascular Dementia Based on Subcortical Shape Analysis. <i>PLoS ONE</i> , 2013, 8, e75602.	1.1	8
137	Neuropsychological Performance and Conversion to Alzheimer's Disease in Early- Compared to Late-Onset Amnesic Mild Cognitive Impairment: CREDOS Study. <i>Dementia and Geriatric Cognitive Disorders</i> , 2012, 34, 156-166.	0.7	25
138	The Localizing and Lateralizing Value of Auras in Lesional Partial Epilepsy Patients. <i>Yonsei Medical Journal</i> , 2012, 53, 477.	0.9	21
139	Clinical Manifestations of Cerebellar Infarction According to Specific Lobular Involvement. <i>Cerebellum</i> , 2010, 9, 571-579.	1.4	38
140	Diffuse large B-cell lymphoma presenting as piriformis syndrome. <i>Muscle and Nerve</i> , 2010, 41, 419-422.	1.0	13
141	Long-term efficacy and tolerability of topiramate as add-on therapy in refractory partial epilepsy: An observational study. <i>Epilepsia</i> , 2009, 50, 1910-1919.	2.6	31
142	Neurocutaneous Melanosis Presenting as Chronic Partial Epilepsy. <i>Journal of Clinical Neurology</i>		